My aim is to help the pharmaceutical industry develop a winning strategy: Dr Rupali Paranjape

My aim is to help the pharmaceutical industry develop a winning strategy: Dr Rupali Paranjape

Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com

The focus in FY 23 for most players would be international markets and ROW exports: Ankit Poddar, director, Candle Partners

The focus in FY 23 for most players would be international markets and ROW exports: Ankit Poddar, director, Candle Partners

Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.

We continue to invest in R&D and new product development: Anish Bafna, CEO & MD, Healthium Medtech

We continue to invest in R&D and new product development: Anish Bafna, CEO & MD, Healthium Medtech

Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans

We have built new AI platforms like REILI to meet current needs: Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India

We have built new AI platforms like REILI to meet current needs: Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India

Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com

Venus Remedies aims to achieve Rs 1000 crore turnover by 2025: Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre

Venus Remedies aims to achieve Rs 1000 crore turnover by 2025: Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre

Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India

Ascent Meditech chalks out ambitious growth plans: Rajiv Mistry, Founder & Managing Director, Ascent Group

Ascent Meditech chalks out ambitious growth plans: Rajiv Mistry, Founder & Managing Director, Ascent Group

Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry

More women than men open up on mental health issues: Krishna Veer Singh, Co-Founder & CEO, Lissun

More women than men open up on mental health issues: Krishna Veer Singh, Co-Founder & CEO, Lissun

Mental health issues are a cause for concern and in a conservative society like India. Thomas C Thottathil spoke to Krishna Veer Singh, Co-Founder and CEO of Lissun, a young start-up working in the space of mental health

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry

Medical devices industry needs reforms:  Mehernosh Daruwalla, Founder & MD, Lotus Surgicals

Medical devices industry needs reforms: Mehernosh Daruwalla, Founder & MD, Lotus Surgicals

The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector

Molbio has pioneered point of care molecular testing: Sriram Natarajan

Molbio has pioneered point of care molecular testing: Sriram Natarajan

Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil

Indian nutraceutical market is expected to touch US $ 18 bn by 2025: Dr R.B Smarta

Indian nutraceutical market is expected to touch US $ 18 bn by 2025: Dr R.B Smarta

The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector

Novaerus devices reduce bio-burden in healthcare facilities: Dilip Patil, Partner, Trivector Biomed

Novaerus devices reduce bio-burden in healthcare facilities: Dilip Patil, Partner, Trivector Biomed

Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.

We are marketing all our products globally: Samit Jain, MD, PLUSS

We are marketing all our products globally: Samit Jain, MD, PLUSS

Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business

We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare

We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare

Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.

Startup

Digitization